Actinium Pharmaceuticals

ATNM · NYSE American

$1.40+$0.08 (+6.06%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $1.32

ATNM analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $4.08 (+191.4% upside)

Low: $3.03
Now: $1.40
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

ATNM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Stephens & Co.	Mar 31, 2026	Maintains	Overweight	$5.00	66%

The case for and against

Updated Dec 15, 2025

Bull case

Actinium Pharmaceuticals Inc. has demonstrated significant advancements in its development of radiotherapies, specifically with its product candidate ATNM-400, which has outperformed standard treatments in preclinical studies. This candidate shows promise for patients with metastatic castration-resistant prostate cancer, particularly those who have limited options after other therapies have failed. The strengthening data around both ATNM-400 and Actimab-A provides a solid foundation for a positive outlook on the company's potential to capture market share in the oncology space, given the ongoing need for effective treatments in difficult-to-treat cancers.

Bear case

Actinium Pharmaceuticals Inc faces significant risks that could negatively impact its stock performance, including the possibility of failed or inconclusive clinical trials for its product candidates, Iomab-B and Actimab-A. Additionally, the company's reliance on securing adequate funding to advance these drugs through the development process presents a critical financial hurdle. These factors collectively contribute to a cautious outlook regarding the company's ability to meet its valuation expectations.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.